News

Deal Announcements

Calimmune Raises Series B Venture Capital

Friday, May 29, 2015 5:33:00 AM PDT | VentureDeal
   Tucson, Arizona  --  Biotechnology company Calimmune has raised $15 million in its second round of institutional venture capital funding.

Calimmune is developing gene therapies that have the potential to help patients with HIV/AIDS.

Investors in the round included Alexandria Venture Investments, RA Capital and other undisclosed investors.

The company said it would use the funding to advance its ongoing HIV/AIDS clinical trials.

Calimmune's CEO is Louis Breton (LinkedIn Profile).

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1